Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAH0968 With or Without CAPEOX in HER2-expressing Advanced/Metastatic Solid Tumors and Gastric Cancer
NCT06504732Phase 3Recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Aug 2024
- Primary completion
- Jul 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of IAH0968 in gastric cancer (GC), solid tumor and colorectal cancer (CRC) (2 cohorts), sponsored by SUNHO BioPharmaceutical. Primary endpoints: Number of Participants Who Experienced At Least One Adverse Event, Number of Participants Who Discontinued Study Treatment Due to an Adverse Event and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
IAH0968
03
Conditions
gastric cancer (GC)solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06504732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504732.